Duke Hematologic Malignancies & Cellular Therapy
@DukeHMCT
Followers
621
Following
270
Media
180
Statuses
1,042
Division within @dukemedicine and multidisciplinary program within @DukeCancer focused in blood cancer/BMT/cell therapy patient care, research, and education.
Durham, NC
Joined May 2019
Don't wanna be here?
Send us removal request.
Explore trending content on Musk Viewer
Edmundo
• 263422 Tweets
CHARLOTTE X TIKTOKLIVE99
• 228971 Tweets
#Narin
• 226687 Tweets
ANILPIN WE ARE THE ONE
• 194506 Tweets
#ปิ่นภักดิ์EP6
• 186729 Tweets
#光る君へ
• 108845 Tweets
KIM TAEHYUNG
• 54227 Tweets
プロジェクトKV
• 53756 Tweets
Zapatero
• 50873 Tweets
東京ドーム
• 39376 Tweets
İdam
• 30738 Tweets
Kostic
• 29906 Tweets
ポルノグラフィティ
• 27650 Tweets
SEVENTEEN AT LOLLAPALOOZA
• 21604 Tweets
NFL Sunday
• 15407 Tweets
ماهر الجازي
• 15325 Tweets
源氏物語
• 15153 Tweets
#降り積もれ孤独な死よ
• 14706 Tweets
LESSONS FROM BIU
• 13654 Tweets
Duke Hematologic Malignancies & Cellular Therapy Retweeted
CONGRESS |
#SOHO2024
| Poster
Harry Erba,
@DukeCancer
, presents a post hoc analysis of QuANTUM-First study assessing the impact of age on efficacy of quizartinib in patients with ND FLT3-ITD+ AML. Among 297 pts achieving CR at the end of induction, CR rates were similar with
0
1
2
How might electronic Patient-Reported Outcomes be best implemented in healthcare? An important discussion in
@JournalGIM
featuring our very own
@tomleblancMD
#PROs
0
1
2
Duke Hematologic Malignancies & Cellular Therapy Retweeted
Cord Blood connect 2024 meeting beginning right now!! There is a donor for everyone 🔝🔝 Joanne Kurtzberg
@Duke_Childrens
Mitch Horwitz
@DukeHMCT
!
@rob_wynn_TdF
good to see you here!! Looking forward to your session about cord blood manipulation and engineering!
0
3
10
Top 10 tips that
#PalliativeCare
doctors should know when caring for patients with
#MPN
, featuring our faculty
@LindsayReinMD
and
@tomleblancMD
, and
@DukeFellows
@A_TaylorMD
!
0
0
2
Congrats to our outstanding trainees,
@KatherineZhouMD
@DukeFellows
and
@ClareE_Anderson
@IMResidencyDuke
, for their
@SocietyofHemOnc
Young Investigator Program scholarships! Here they are presenting their work on lymphoid malignancies at
#SOHO24
.
Mentor(s):
@ChenyuLinMD
0
4
15
Check out this large U.S. consortium study describing how prior inotuzumab exposure relates to outcomes in patients with
#ALL
receiving
#Tecartus
, recently published in
@BloodAdvances
and featuring our faculty
@ChenyuLinMD
!
#ROCCA
#leusm
#CART
👉👈
0
0
4
There is a great need for heme/onc fellowships to teach how to communicate about clinical trials, a paper featuring our own
@AndreaSitlinger
.
@LLSusa
supports a workshop at
@dukemedicine
that does exactly this!
#MedEd
#disparities
0
0
1
Take a look at this wonderful reflection piece in
@ASTCT_Journal
by our
@DukeHMCT
chief
@stefani23697335
: "Inspiration From Leaders Who Dare to Care".
0
1
6
Duke Hematologic Malignancies & Cellular Therapy Retweeted
Check out our national
@VAResearch
study of BTK inhibitor use in severe renal failure! No current guidance on FDA labels.
#CLLsm
@BrJHaem
👉 BTK inhibitors feasible even in eGFR < 30
👉⬇️ dose can ⬆️ duration of tx without impacting efficacy
1
1
4
Duke Hematologic Malignancies & Cellular Therapy Retweeted
🎥 Harry Erba (
@DukeCancer
) provides a comprehensive overview of menin inhibition in AML, discussing the mechanism of action, current key data, and the possibility of predicting the efficacy of these agents in individual patients:
👉 👈
#AMLsm
#Leusm
0
2
2
Duke Hematologic Malignancies & Cellular Therapy Retweeted
From
@ASCOPost
"What Is the Optimal First-Line Therapy for Chronic Lymphocytic Leukemia?" feat.
@dbranderMD
#PanPacificLymphomaConference
Read:
0
2
1
Duke Hematologic Malignancies & Cellular Therapy Retweeted
Important talk by
@ARamakrishnanMD
on how to enhance access and safety of outpatient
#CART
. Personalizing based on patient and product-specific characteristics is critical. Remote monitoring may help!
@btfoundation
#SCTS24
@DukeHMCT
will be piloting a novel multi-vital sign
0
4
5
Duke Hematologic Malignancies & Cellular Therapy Retweeted
🎙️ Tune in to the
@Medscape
InDiscussion podcast w/
@DukeHMCT
faculty
@LindsayReinMD
. Dr. Rein dives into the evolving treatment landscape for
#myelofibrosis
, discussing JAK inhibitors, transplant options, & more. Don't miss this insightful conversation
🔗
0
1
1
🚨New RN Job Opening
@DukeCancer
@DukeHMCT
- Cellular Therapy Coordinator🚨
Join our established team leading Duke's growing commercial CAR-T and TIL program! RN, BSN required; MSN preferred.
@oncologynursing
#CART
0
0
1
An important paper featuring
@tomleblancMD
on the benefits of a stepped palliative care model for patients with
#LungCancer
. Stepped-care model => lower care burden with similar
#QoL
outcomes.
#lcsm
@JAMA_current
0
1
1
New
@CIBMTR
publication in
@BloodJournal
on the real-world outcomes of Axi-cel in DLBCL by race/ethnicity, featuring our new faculty
@hongsmd
as a co-author!
#CART
#lymsm
0
0
0
A
@dukemedicine
centennial spotlight on the long and distinguished career of Dr. Nelson Chao, 27 years as division chief of
@DukeHMCT
and former
@ASTCT
president (2005-2006).
0
1
19
New clinical trial now open
@DukeCancer
: OLYMPIA-3 study evaluating a novel CD3xCD20 bispecific antibody Odronextamab + CHOP for 1st line treatment of
#DLBCL
. PI is Dr. Jie Wang in the section of lymphoma within
@DukeHMCT
.
#lymsm
#lymphoma
0
0
1